UB Paderborn / Katalog / Suche / in CDI

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis

Trials, 2022-06, Vol.23 (1), p.474-7, Article 474

2022

Volltextzugriff (PDF)

Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine-Lamivudine plus Nevirapine and Zidovudine-Lamivudine plus Abacavir

The Journal of infectious diseases, 2010-01, Vol.201 (1), p.106-113

2010

Volltextzugriff (PDF)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial

PloS one, 2014-03, Vol.9 (3), p.e90772

2014

Volltextzugriff (PDF)

Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1

Antimicrobial Agents and Chemotherapy, 2011-04, Vol.55 (4), p.1806-1809

2011

Volltextzugriff (PDF)

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2012-07, Vol.308 (4), p.353

2012

Volltextzugriff (PDF)

T-wave morphology abnormalities in the STREAM stage 1 trial

Expert opinion on drug safety, 2024-04, Vol.23 (4), p.469-476

2024

Volltextzugriff (PDF)

Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study

The lancet HIV, 2015-12, Vol.2 (12), p.e530-e539

2015

Volltextzugriff (PDF)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria

PloS one, 2013, Vol.8 (2), p.e57580-e57580

2013

Volltextzugriff (PDF)

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

Clinical infectious diseases, 2014-04, Vol.58 (7), p.1023-1026

2014

Volltextzugriff (PDF)

Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa

Journal of antimicrobial chemotherapy, 2017-05, Vol.72 (5), p.1450-1455

2017

Volltextzugriff (PDF)

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa

AIDS research and human retroviruses, 2015-10, Vol.31 (10), p.1032

2015

Volltextzugriff (PDF)

Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial

The Pediatric infectious disease journal, 2003-01, Vol.22 (1), p.56-62

2003

Volltextzugriff (PDF)

Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring

Journal of acquired immune deficiency syndromes (1999), 2010-10, Vol.55 (2), p.277

2010

Volltextzugriff (PDF)

Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting

Journal of acquired immune deficiency syndromes (1999), 2010-06, Vol.54 (2), p.215

2010

Volltextzugriff (PDF)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

The Lancet (British edition), 2022-11, Vol.400 (10366), p.1858-1868

2022

Volltextzugriff (PDF)

Interval-censored survival time data: confidence intervals for the non-parametric survivor function

Statistics in medicine, 2004-04, Vol.23 (7), p.1131-1145

2004

Volltextzugriff (PDF)

The activity of low-clearance liposomal amikacin in experimental murine tuberculosis

Journal of antimicrobial chemotherapy, 2001-12, Vol.48 (6), p.869-876

2001

Volltextzugriff (PDF)

A virological benefit from an induction/maintenance strategy: the forte trial

Antiviral therapy, 2007, Vol.12 (1), p.47-54

2007

Volltextzugriff (PDF)

TIMING AND INTERPRETATION OF TESTS FOR DIAGNOSING PERINATALLY ACQUIRED HEPATITIS C VIRUS INFECTION

The Pediatric infectious disease journal, 2001-07, Vol.20 (7), p.715-716

2001

Volltextzugriff (PDF)

Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial

The Lancet global health, 2023-02, Vol.11 (2), p.e265-e277

2023

Volltextzugriff (PDF)

A Single CD4 Test with 250 Cells/Mm.sup.3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria

PloS one, 2013-02, Vol.8 (2), p.e57580

2013

Volltextzugriff (PDF)

High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial: e90772

PloS one, 2014-03, Vol.9 (3)

2014

Volltextzugriff (PDF)

Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?

Journal of antimicrobial chemotherapy, 1999-03, Vol.43 (3), p.379-388

1999

Volltextzugriff (PDF)

Global variations in pubertal growth spurts in adolescents living with perinatal HIV

AIDS (London), 2023-08, Vol.37 (10), p.1603-1615

2023

Volltextzugriff (PDF)

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study

PLoS medicine, 2018-01, Vol.15 (1), p.e1002491-e1002491

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis

Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine-Lamivudine plus Nevirapine and Zidovudine-Lamivudine plus Abacavir

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial

Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

T-wave morphology abnormalities in the STREAM stage 1 trial

Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa

Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial

Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring

Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Interval-censored survival time data: confidence intervals for the non-parametric survivor function

The activity of low-clearance liposomal amikacin in experimental murine tuberculosis

A virological benefit from an induction/maintenance strategy: the forte trial

TIMING AND INTERPRETATION OF TESTS FOR DIAGNOSING PERINATALLY ACQUIRED HEPATITIS C VIRUS INFECTION

Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial

A Single CD4 Test with 250 Cells/Mm.sup.3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria

High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial: e90772

Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?

Global variations in pubertal growth spurts in adolescents living with perinatal HIV

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study

Suchergebnisse filtern